

Document allergies on approved form and ensure medication reconciliation has been reviewed as per organizational process

Atlantic Anti-Platelet Initiative (AAPI) Oral Antiplatelet Therapy for Non-ST Elevation Acute Coronary Syndrome (NSTEMACS) Order Set

NSTEMACS Patient: Requiring Urgent Invasive Assessment

Refer to Associated Document: AAPI Algorithm for Oral Antiplatelet: Acute P2Y₁₂ for NSTEMACS Patient - Requires Urgent Invasive Assessment

Acetylsalicylic Acid

For patient who has NOT taken acetylsalicylic acid and has no contraindications

Non-enteric coated acetylsalicylic acid _____ mg PO loading dose (160 – 325 mg)

Then Enteric coated acetylsalicylic acid 81 mg PO daily

For patient already taking daily maintenance acetylsalicylic acid therapy

Enteric coated acetylsalicylic acid 81 mg PO daily

And

P2Y₁₂ Inhibitor

*****Withhold P2Y₁₂ inhibitor therapy ONLY if clinical features exist that increase the likelihood of urgent cardiac surgery*****

P2Y₁₂ inhibitor therapy withheld

clopidogrel _____ mg PO loading dose (300 – 600 mg as per local protocols)

Then clopidogrel 75 mg PO daily

NSTEMACS: Scheduled for Planned Invasive Assessment OR Planned Medical Management

Refer to Associated Document: AAPI Algorithm for Oral Antiplatelet: Acute P2Y₁₂ for NSTEMACS Patient - Planned Invasive Assessment or Planned Medical Management

Acetylsalicylic Acid

For patient who has NOT taken acetylsalicylic acid and has no contraindications

Non-enteric coated acetylsalicylic acid _____ mg PO loading dose (160 – 325 mg)

Then Enteric coated acetylsalicylic acid 81 mg PO daily

For patient already taking daily maintenance acetylsalicylic acid therapy

Enteric coated acetylsalicylic acid 81 mg PO daily

And

P2Y₁₂ Inhibitor

For patient at high clinical risk (e.g. GRACE Risk Score greater than 140 or TIMI score 5 - 7) but not at high risk of bleeding

*****Risk factors for bleeding include older age, female sex, lower body weight, renal insufficiency, history of previous bleeding, anemia, use of invasive procedures*****

Refer to Associated Document: GRACE and TIMI Risk Scores

ticagrelor 180 mg PO loading

Then ticagrelor 90 mg PO BID dose

*****ticagrelor can be prescribed to patients who received prior clopidogrel loading*****

For patient not at high clinical risk and with no other contraindications

clopidogrel 300 mg PO loading dose

Then clopidogrel 75 mg PO daily

Submitted by:

Read Back

Practitioner:
